<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>DL</div>
LALPATHLAB -- India Stock  

INR 1,717  99.35  6.14%

Do you want to know what the current value of DR LAL PATHLABS is today? DR LAL PATHLABS owns a latest Real Value of 1622.78 per share. The recent price of the firm is 1717.1. At this time, the firm appears to be overvalued. Our model computes the value of DR LAL PATHLABS from examining the firm fundamentals such as return on asset of 13.73 %, current valuation of 121.18 B, and shares owned by insiders of 60.36 % as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise locking in undervalued equities and disposing overvalued equities since, sooner or later, asset prices and their ongoing real values will draw towards each other.

Search Valuation

DR LAL Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as DR LAL's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
8th of July 2020
Real Value
DR LAL is very steady asset. Calculation of real value of DR LAL PATHLABS is based on 3 months time horizon. Increasing DR LAL PATHLABS time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
LowEstimated ValueHigh

DR LAL Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining DR LAL's current stock value. Our valuation model uses many indicators to compare DR LAL value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DR LAL competition to find correlations between indicators driving DR LAL's intrinsic value. More Info.
DR LAL PATHLABS is currently regarded as number one stock in price to earning category among related companies. It is currently regarded as number one stock in price to book category among related companies fabricating about  0.22  of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for DR LAL PATHLABS is roughly  4.57 

About DR LAL Valuation

The Macroaxis Equity Valuation Mechanism determines the current worth of DR LAL PATHLABS on a weekly bases. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of DR LAL PATHLABS. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of DR LAL PATHLABS based exclusively on its fundamental and basic technical indicators. By analyzing DR LAL's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of DR LAL's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of DR LAL. We calculate exposure to DR LAL's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to DR LAL's related companies.
Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India. DR LAL operates under Diagnostics Research classification in India and is traded on National Stock Exchange of India.
Additionally, see Stocks Correlation. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page